<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51880">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813630</url>
  </required_header>
  <id_info>
    <org_study_id>DA3002_TS_III (Version 1.2)</org_study_id>
    <nct_id>NCT01813630</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Efficacy and Safety of DA-3002</brief_title>
  <official_title>Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A comparison of annualized height velocity between the DA-3002 treated group and the Genotropin® treated group after 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>A difference of Height Standard Deviation Score between the DA treated group and the Genotropin® treated group after 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The change of antibodies to growth hormone</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Turner's Syndrome</condition>
  <arm_group>
    <arm_group_label>DA-3002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotropin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-3002</intervention_name>
    <arm_group_label>DA-3002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotropin®</intervention_name>
    <arm_group_label>Genotropin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Turner's Syndrome through chromosome analysis

          -  The chronological age: 2≤AGE≤12

          -  The yearly growth rate should be less than 6cm; the bone age should be equal or less
             than 12; the height ≤ 10th percentile for the heights of their agemates

          -  Before the adolescence, Tuner stage I (breast)

          -  Normal thyroid function

        Exclusion Criteria:

          -  Growth hormone was administered for 12 months or longer in the past

          -  Treated with estrogen or adrenal androgens for 12 months or longer in the past

          -  Malignancy, CNS Trauma, Psychiatric Disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Wook Yoo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung Kyu Suh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheol Woo Ko, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kee Hyoung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Kyu Jin, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choong Ho Shin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Soon Hwang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aju University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Seong Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Children's Hospital Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Young Jeong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Jong Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heon Suk Han, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Kyu Jin, M.D., Ph.D.</last_name>
    <phone>82-2-1599-3114</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Dong Kyu, M.D., Ph.D.</last_name>
      <phone>82-2-1599-3114</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>March 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Turner's Syndrome</keyword>
  <keyword>Short Stature</keyword>
  <keyword>Dwarfism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
